ERBB2 and breast cancer: Additional future studies of interest include evaluating the efficacy of sabizabulin in acquired taxane-resistant HER2+ breast cancer models, and downstream genetic profiling to discover any conserved mechanisms of taxane resistance that are overcome by sabizabulin in the TNBC and HER2+ breast cancer subtypes.